VILEPLUME
Well-Known Member
I didn't know you were such a stud. Got a picture to back that up or was it just the ugly French girls?
Pandemic 2020
- Thread starter Jimdamick
- Start date
- Status
CunningCanuk
Well-Known Member
I wonder if you’ve even been to Quebec now.
I scored a bit. No pictures, I’m a hideous looking individual but, unlike you, I don’t have a chip on my shoulder and a much more pleasing personality.
VILEPLUME
Well-Known Member
Not only lived there but I had a Quebec health card. Shit, I even still have a 514 number because the plans are so cheap there.
I know you have a great personality, you dont need to keep reminding us.
DIY-HP-LED
Well-Known Member
Oh I'm just poking the stick.
There are also many Canadians unfortunately making fun of Americans right now and laughing at them. I try to laugh with them sometimes because of the sheer stupidity of it all, but I cry along with them too from time to time. I figure when your friend is down you lend a helping hand to get him on his feet again and stand by him until he does, you don't kick them in the head. We learn bitter lessons in life, both as individuals and as nations, America didn't just touch the hot stove top, it leaned on it and roasted it's hand, such lessons are not quickly forgotten.
CunningCanuk
Well-Known Member
No place is perfect and I have a problem with Quebec’s provincial government and their racist laws. If you talked about that I would have more respect for your position.
It’s only fair. Like I said, I’m hideous looking.
VILEPLUME
Well-Known Member
It a tragedy what is happening in America. From the border children in cages to a pandemic with 1/3 of the country with no healthcare, to still to this day in 2020 many racist law enforcement.
Making fun of the U.S government is all good fun, but nothing but sympathy for the low income people.
VILEPLUME
Well-Known Member
Have you driven around Montreal? They let the mob control their construction contracts and the roads are terrible.
Dr.Amber Trichome
Well-Known Member
I’d move to Canada because I love Justin. He is so cool. How long will he be able to be in charge? I love his beard , he is so down to earth.
VILEPLUME
Well-Known Member
Dr.Amber Trichome
Well-Known Member
Oh pleeeeeeaaaassee!!I am more interested in his intellectual capacity. that bitch is in in need of some sexual satisfaction she can’t find with her creepy limp dick husband. She can keep dreaming. he wouldn’t touch that skank.
DIY-HP-LED
Well-Known Member
He just cut a deal with the NDP (left) party and currently has a minority government in parliament, elections must be held every 5 years, but the government party can call them whenever they want or if they lose a confidence or budget vote in parliament. The last Canadian federal election was held on October 21, 2019, so perhaps 2024 and then he goes for another election.
In Canada you vote for your MP, the party picks the leader and he becomes PM, sometimes someone else will become PM if the PM becomes sick or resigns.
VILEPLUME
Well-Known Member
Have you seen the new Borat movie on Amazon Prime? Justin makes a surprise appearance at the start of the movie.
Dr.Amber Trichome
Well-Known Member
No not yet but I will! I love the Borat movies. I just watched one last week. The one where he goes to America, lands in NYC and falls in love with Pamela Anderson and then travels across the country to California. Good one!
topcat
Well-Known Member
Hilarious. Dullard J. Drumpf should include it in his standup routine. "Covid, Covid, Covid." "Covid, Covid, Covid, Covid, Covid." Like a little boy who just learned a new word.
DIY-HP-LED
Well-Known Member
Trump will enter the American lexicon, as in: Man you really Trumped that one up!
captainmorgan
Well-Known Member
About 1 in 6 fully recovered COVID-19 patients still test positive for the virus
Researchers add that recovered COVID-19 patients still dealing with a sore throat and stuffy nose were more likely to have a new positive test.
www.studyfinds.org
DIY-HP-LED
Well-Known Member
Science | AAAS
President Donald Trump and Food and Drug Administration Commissioner Stephen Hahn (right) met with Daniel O’Day (left), CEO of Gilead Sciences, when remdesivir received an emergency use authorization in May.
AP PHOTO/ALEX BRANDON
The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug
By Jon Cohen, Kai KupferschmidtOct. 28, 2020 , 7:05 PM
Science’s COVID-19 reporting is supported by the Pulitzer Center and the Heising-Simons Foundation.
October was a good month for Gilead Sciences, the giant manufacturer of antivirals headquartered in Foster City, California. On 8 October, the company inked an agreement to supply the European Union with its drug remdesivir as a treatment for COVID-19—a deal potentially worth more than $1 billion. Two weeks later, on 22 October, the U.S. Food and Drug Administration (FDA) approved remdesivir for use against the pandemic coronavirus SARS-CoV-2 in the United States—the first drug to receive that status. The EU and U.S. decisions pave the way for Gilead’s drug into two major markets, both with soaring COVID-19 cases.
But both decisions baffled scientists who have closely watched the clinical trials of remdesivir unfold over the past 6 months—and who have many questions about remdesivir's worth. At best, one large, well-designed study found remdesivir modestly reduced the time to recover from COVID-19 in hospitalized patients with severe illness. A few smaller studies found no impact of treatment on the disease whatsoever. Then, on 15 October—in this month’s decidedly unfavorable news for Gilead— the fourth and largest controlled study delivered what some believed was a coup de grâce: The World Health Organization’s (WHO’s) Solidarity trial showed that remdesivir does not reduce mortality or the time COVID-19 patients take to recover.
FDA did not respond to Science’s request to discuss why it opted against convening the committee, noting only that it is “at the discretion” of division directors. But FDA’s inaction stands in sharp contrast to its handling of potential COVID-19 vaccines. Last week, the agency convened an advisory group to discuss the mere possibility of such a vaccine passing regulatory muster.
As to the EU agreement, Gilead confirmed to Science that WHO in “late September” provided the company with a manuscript about the study results, but a spokesperson for the European Commission, the EU executive arm, said these weren’t revealed during its negotiations. The company has aggressively called into question the validity of the Solidarity data, in part because the study was carried out in vastly different countries around the world with different health care standards. In a 15 October statement, Gilead went so far as to say “it is unclear if any conclusive findings can be drawn from the study results.”
That criticism has angered investigators in the Solidarity study, including Marie-Paule Kieny, director of research at the French medical research agency INSERM and a former WHO officer. “It's appalling to see how Gilead tries to badmouth the Solidarity trial,” Kieny says. “Pretending the trial has no value because it is in low-income countries is just prejudice.”
more...
DIY-HP-LED
Well-Known Member
Death Rates Have Dropped for Seriously Ill Covid Patients (Published 2020)
Survival rates have improved with medical advances and less crowded hospitals, studies say. But the latest record-breaking surge in infections could reverse the gains.
Death Rates Have Dropped for Seriously Ill Covid Patients
Survival rates have improved with medical advances and less crowded hospitals, studies say. But the latest record-breaking surge in infections could reverse the gains.
The coronavirus struck the United States earlier this year with devastating force. In April, it killed more than 10,000 people in New York City. By early May, nearly 50,000 nursing home residents and their caregivers across the country had died.
But as the virus continued its rampage over the summer and fall, infecting nearly 8.5 million Americans, survival rates, even of seriously ill patients, appeared to be improving. At one New York hospital system where 30 percent of coronavirus patients died in March, the death rate had dropped to 3 percent by the end of June.
Doctors in England observed a similar trend. “In late March, four in 10 people in intensive care were dying. By the end of June, survival was over 80 percent,” said John M. Dennis, a University of Exeter Medical School researcher who is first author of a paper about improved survival rates in Britain, accepted for publication in the journal Critical Care Medicine. “It was really quite dramatic.”
Though the virus has been changing slowly as it spreads, and some have speculated that it has become more easily transmissible, most scientists say there is no solid evidence that it has become either less virulent, or more virulent. As elderly people sheltered inside and took precautions to avoid infection, however, more of the hospitalized patients were younger adults, who were generally healthier and more resilient. By the end of August, the average patient was under 40.
Were the lower death rates simply a function of the demographic changes, or a reflection of real progress and medical advances in treatment that blunted the impact of the new pathogen?
Researchers at NYU Langone Health who zeroed in on this question, analyzing the outcomes of more than 5,000 patients hospitalized at the system's three hospitals from March through August, concluded the improvement was real, not just a function of changing demographics. Even when they controlled for differences in the patients’ age, sex, race, underlying health problems and severity of Covid symptoms — like blood oxygen levels at admission — they found that death rates had dropped significantly, to 7.6 percent in August, down from 25.6 percent in March.
“This is still a high death rate, much higher than we see for flu or other respiratory diseases,” said Dr. Leora Horwitz, director of NYU Langone’s Center for Healthcare Innovation & Delivery Science and senior author of the paper in Journal of Hospital Medicine. “I don’t want to pretend this is benign. But it definitely is something that has given me hope.”
Other doctors agreed. “The mortality rates are way lower now,” said Dr. Robert A. Phillips, chief physician executive at Houston Methodist and author of a research letter in JAMA that compared the first and second surges of Covid-19 patients in Houston. But he emphasized that the disease remains “not only deadly — 10 times more deadly probably than a bad influenza — but it also has long-term complications. You don’t have that from the flu.”
While the studies evaluated the death rate, they did not assess the burden of what Dr. Phillips called “post-Covid syndrome,” which leaves many patients with lasting respiratory and neurologic problems, cardiac complications, and other lingering issues.
“It’s relatively easy to measure death, but that doesn’t capture all the other health issues,” said Dr. Preeti Malani, an infectious disease expert at the University of Michigan. Many hospital patients face grueling and protracted recoveries and may require long-term care, while even those who had mild bouts of disease are often left with continuing health problems, like headaches, chronic fatigue or cognitive problems. “It will take a long time to understand the full clinical spectrum of this disease.”
And even as the rates of death decline, the raw numbers of deaths are expected to rise, driven by the increasing cases across the country. According to combined modeling forecasts cited by the Centers for Disease Control and Prevention, the number of weekly deaths in the United States could surpass 6,000 by Nov. 7, and cumulative deaths could reach 250,000 by Nov. 21.
The study from England analyzed the outcomes of 14,958 critical care and intensive care patients hospitalized throughout England from March 1 to May 30. Even after adjusting for differences in age, sex, ethnicity and underlying health conditions, the authors concluded survival improved by about 10 percent each week after the end of March for patients in critical care and high intensity care units (the English study did not adjust for severity of Covid-19 illness at admission).
A combination of factors contributed to the improved outcomes of hospital patients, the authors of the two studies and other experts said. As clinicians learned how to treat the disease, incorporating the use of steroid drugs and non-drug interventions, they were better able to manage it.
The researchers also credited heightened community awareness, and patients seeking care earlier in the course of their illness. Outcomes may also have improved as the load on hospitals lightened and there was less pressure on the medical staff, both of which had been overwhelmed by a surge of patients in the spring.
“We don’t have a magic bullet cure, but we have a lot, a lot of little things, that add up,” Dr. Horwitz said. “We understand better when people need to be on ventilators and when they don’t, and what complications to watch for, like blood clots and kidney failure. We understand how to watch for oxygen levels even before patients are in the hospital, so we can bring them in earlier. And of course, we understand that steroids are helpful, and possibly some other medications.”
For clinicians combating the disease, caused by a new pathogen that was unknown before it emerged in Wuhan, China, late last year, the learning curve has been steep. Doctors shared information and gleaned insights from a barrage of studies shared with unprecedented speed, but there were also missteps. At first, the focus was on the illness’ effects on the lungs; understanding the deleterious impact on other organs came later.
Early on, physicians were placing patients on mechanical ventilators to assist with their breathing; over time they learned to position patients on their stomachs and provide them with supplemental oxygen through less invasive means, and postpone ventilation or avoid it altogether if possible.
By mid-June, clinical trials in England had proven that treatment with a cheap steroid drug, dexamethasone, reduced deaths of patients on ventilators by one-third, and death in patients getting supplemental oxygen by one-fifth. But the early recommendations from China and Italy were “to absolutely not use steroids, even though a lot of us thought it made sense to use them,” said Dr. Gita Lisker, a critical care physician at Northwell Health. “I think it’s making a big difference. But when we started with this in March, the data and recommendations from China and Italy were saying, ‘Do not use them, steroids are bad.’”
Doctors also weren’t aware at first that the Covid-19 illness caused by the new virus caused life-threatening blood clots. Now patients are put on blood thinners early on in treatment when necessary.
But the other problem in the spring was that hospitals in hard-hit areas like New York City were overwhelmed. Doctors who hadn’t worked in critical care for many years were being drafted to care for seriously ill patients, nurses were short-staffed, and equipment was in short supply. “There was a sheer overwhelming tidal wave that overtook the health care system,” Dr. Lisker said. “You had critical care units run by doctors who hadn’t done critical care in 10 years, or even ever.”
She added, “There is no question that whether you lived or died in April, some of it had to do with what unit you landed in.”
Indeed, she said, “The whole idea of flattening the curve was to avoid overwhelming the health care system.”
Medical experts are worrying that the surges in cases around the country could reverse or roll back those gains. The number of hospitalized Covid patients has increased by 40 percent over the last month, and more than 41,000 patients are now hospitalized in the United States. Hospital administrators in Idaho, Utah and Kansas City, Mo., have warned they are already close to capacity. Some have turned ambulances away, and others are drawing up plans to ration care if they run out of beds and have said they may be forced to transfer patients to facilities in other states.
more...
captainmorgan
Well-Known Member
On our current trajectory they are now saying by christmas it will be up to 3,000 dead each day.
DIY-HP-LED
Well-Known Member
Merry Christmas from Donald America, but he will still feel aggrieved and mistreated. If he loses in a landslide I think he will try to hold post election rallies, just to feel the love. That's what's going on now, the rallies are doing far more harm than good to Donald's campaign (there is research on this), they are being held solely to meet Donald's emotional needs. Donald will need bigly emotional support after the election and if he loses in a landslide he will need someone to vent, bleat and whine to, so will his fans. I predict post election rallies where Donald will whine about a rigged election and encourage his fans to take up arms against the "deep state".
- Status